

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

FINANCIAL RESULTS
FOR THE YEAR ENDED DECEMBER 31, 2023

This announcement is issued by Qyuns Therapeutics Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Note to Rule 13.49(1) of The Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Shareholders and potential investors of the Company are reminded that the preliminary results of the Group for the year ended December 31, 2023 (as prescribed by Rule 13.49(1) of the Listing Rules) were included in “Unaudited Preliminary Financial Information for the Year Ended December 31, 2023” in Appendix III to the prospectus of the Company dated March 12, 2024, which is available for viewing on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.qyuns.net).

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, March 28, 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.